Form 4: BioLife Solutions Executive Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 216 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions, sold 216 shares of common stock on November 26, 2024.
- The shares were sold at a price of $27.2 per share.
- The transaction was executed under a pre-existing Rule 10b5-1 trading plan adopted on February 24, 2022.
- The sale was to cover tax withholding obligations related to the vesting of restricted stock.
- Following the transaction, Ms. Aebersold directly owns 60,484 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.
Industry Context
This is a routine transaction for executives who often use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading. It is common for executives to sell shares to cover tax obligations related to vesting of restricted stock.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and life sciences sectors, such as Thermo Fisher Scientific and Danaher Corporation.
- These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
- The sale of 216 shares by Ms. Aebersold is a relatively small transaction compared to the overall volume of trading in BioLife Solutions stock and is not unusual for executives managing their personal finances.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the stock price given the small volume and pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 02/24/2022 | Date the Rule 10b5-1 trading plan was adopted by Sarah Aebersold. |
| 11/26/2024 | Date of the stock sale transaction. |
| 11/29/2024 | Date the Form 4 was signed. |
Keywords
BioLife Solutions, BLFS, insider trading, Form 4, stock sale, Rule 10b5-1, Sarah Aebersold, executive compensation, share transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.